Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Water. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 14/20 | 0.81 |
| ▸ | OPRK1 known ✓ | P41145 | 11/20 | 0.81 |
| ▸ | OPRD1 known ✓ | P41143 | 5/20 | 0.81 |
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.72 |
| ▸ | PDE4D known ✓ | Q08499 | 1/20 | 0.72 |
| ▸ | PDE3A known ✓ | Q14432 | 1/20 | 0.72 |
| ▸ | MRGPRX2 | Q96LB1 | 3/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL30166501 | 1.00 | OPRM1 (0.81) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| Water SCHEMBL29938850 | 1.00 | OPRM1 (0.81) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| SCHEMBL29479412 | 0.99 | OPRM1 (0.82) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| SCHEMBL24579 | 0.99 | OPRM1 (0.82) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| Hydrochloric Acid SCHEMBL28121142 | 0.98 | OPRM1 (0.81) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| SCHEMBL27734251 | 0.92 | OPRM1 (0.77) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| Codeine SCHEMBL7936665 | 0.92 | OPRM1 (0.77) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| SCHEMBL12830850 | 0.90 | OPRM1 (1.00) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| SCHEMBL14107503 | 0.90 | OPRM1 (1.00) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| SCHEMBL14153815 | 0.90 | OPRM1 (1.00) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102740854-A | Loxoprofen-containing pharmaceutical composition | KOWA CO | 2012-10-17 | — | — | CN | claimed |
| EP-4393512-B1 | COMPOSITION FOR PHARMACEUTICAL TABLET, PHARMACEUTICAL TABLET USING THE SAME, AND MANUFACTURING METHOD THEREOF | MITSUBISHI CHEM CORP (JP) | 2025-10-01 | — | — | EP | disclosed |
| WO-2025105451-A1 | SOLID PREPARATION | 第一三共ヘルスケア株式会社 | 2025-05-22 | — | — | WO | disclosed |
| WO-2025100523-A1 | METHOD FOR PRODUCING SOLID PREPARATION, AND TABLETS | 第一三共ヘルスケア株式会社 | 2025-05-15 | — | — | WO | disclosed |
| US-20250115919-A1 | COMPOSITIONS AND METHODS RELATED TO APTAMER-BASED COLORIMETRIC ASSAYS | NORTH CAROLINA STATE UNIVERSITY | 2025-04-10 | — | — | US | disclosed |
| CN-119278035-A | Solid preparation and method for producing the same | 第一三共健康事业株式会社 | 2025-01-07 | — | — | CN | disclosed |
| CN-113038933-B | Oral pharmaceutical preparation containing ibuprofen | SS制药株式会社 | 2024-11-12 | — | — | CN | disclosed |
| EP-4393512-A1 | COMPOSITION FOR MEDICINAL TABLET, MEDICINAL TABLET OBTAINED USING SAME, AND PRODUCTION METHOD THEREFOR | Mitsubishi Chemical Corporation (JP) | 2024-07-03 | — | — | EP | disclosed |
| US-20240173260-A1 | COMPOSITION FOR PHARMACEUTICAL TABLET, PHARMACEUTICAL TABLET USING THE SAME, AND MANUFACTURING METHOD THEREOF | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-05-30 | — | — | US | disclosed |
| CN-117836005-A | Composition for pharmaceutical tablet, pharmaceutical tablet using the same, and method for producing the same | 三菱化学株式会社 | 2024-04-05 | — | — | CN | disclosed |
| CN-105377303-A | Orally disintegrating tablet | SANWA KAGAKU KENKYUSHO CO | 2016-03-02 | — | — | CN | disclosed |
| US-8900602-B2 | Disintegrating particle composition and orally rapidly disintegrating tablet | FUJI CHEMICAL INDUSTRY CO., LTD. (JP) | 2014-12-02 | — | — | US | disclosed |
| US-20130064890-A1 | PHARMACEUTICAL FORMULATION BASED ON IBUPROFEN AND CODEINE HAVING IMPROVED STABILITY | FARMASIERRA MANUFACTURING, S.L. (ES) | 2013-03-14 | — | — | US | disclosed |
| EP-2554164-A1 | PHARMACEUTICAL FORMULATION BASED ON IBUPROFEN AND CODEINE HAVING HAVING IMPROVED STABILITY | Farmasierra Manufacturing, S.L. (ES) | 2013-02-06 | — | — | EP | disclosed |
| CN-102740854-A | Loxoprofen-containing pharmaceutical composition | KOWA CO | 2012-10-17 | — | — | CN | disclosed |
| US-20120165413-A1 | DISINTEGRATING PARTICLE COMPOSITION AND ORALLY RAPIDLY DISINTEGRATING TABLET | FUJI CHEMICAL INDUSTRY CO., LTD. (JP) | 2012-06-28 | — | — | US | disclosed |
| US-20120156261-A1 | DISINTEGRATING PARTICLE COMPOSITION AND ORALLY RAPIDLY DISINTEGRATING TABLET | FUJI CHEMICAL INDUSTRY CO., LTD. (JP) | 2012-06-21 | — | — | US | disclosed |
| EP-2465540-A1 | DISINTEGRATING PARTICLE COMPOSITION AND ORALLY RAPIDLY DISINTEGRATING TABLET | FUJI CHEMICAL INDUSTRY CO., LTD. (JP) | 2012-06-20 | — | — | EP | disclosed |
| EP-2465539-A1 | DISINTEGRATING PARTICLE COMPOSITION AND ORALLY RAPIDLY DISINTEGRATING TABLET | FUJI CHEMICAL INDUSTRY CO., LTD. (JP) | 2012-06-20 | — | — | EP | disclosed |
| US-7008939-B2 | Use of weak opioids and mixed opioid agonists/antagonists for treatment of urinary incontinence | GRUENENTHAL GMBH (DE) | 2006-03-07 | — | — | US | disclosed |